Publication | Closed Access

Tasimelteon for non-24-hour sleep–wake disorder in totally blind people (SET and RESET): two multicentre, randomised, double-masked, placebo-controlled phase 3 trials

Sleep MedicineSleep HealthSleepSleep DisordersPlacebo-controlled Phase 3Sleep DisorderMedicineNon-24-hour Sleep–wake DisorderDisabilityRehabilitationNeurologySleep PhysiologyBlind PeopleVisual ImpairmentSleep DeprivationSocial Sciences